Duarte Ira 4

What Happened

• Ira Duarte, Chief Financial Officer of Heron Therapeutics (HRTX), received equity awards on January 30, 2026: 216,562 restricted stock units (RSUs) and 216,561 performance stock units (PSUs), a total of 433,123 derivative units. Each award was reported at $0.00 (no cash purchase); these are grants (transaction code A), not market purchases or sales.

Key Details

• Transaction date: January 30, 2026; Form 4 filed February 3, 2026 (filing within required 2 business days).
• Award details and price: 216,562 RSUs @ $0.00 and 216,561 PSUs @ $0.00 (derivative awards, total 433,123 units).
• Shares owned after transaction: not specified in this filing.
• Notable footnotes:
  • RSUs convert one-for-one into common stock and vest in 16 equal quarterly installments beginning one quarter after the grant (footnotes F1, F2).
  • PSUs convert one-for-one into common stock, vest in 16 equal quarterly installments beginning one quarter after the grant, and are subject to a net product sales revenue target for fiscal 2026 as reported in the issuer’s Form 10-K (footnotes F3, F4).
• Transaction type: Award/grant (compensation/retention), not a purchase or sale.

Context

• These awards are typical executive compensation/retention vehicles: RSUs provide time-based equity while PSUs add a performance condition tied to company sales for 2026. Because they are awards (derivatives that convert to common shares upon vesting and/or performance achievement), they do not indicate an immediate insider buy or sell.